Zobrazeno 1 - 10
of 24
pro vyhledávání: '"E. A. Gilyazitdinova"'
Autor:
A. L. Melikyan, I. N. Subortseva, E. A. Gilyazitdinova, T. I. Koloshejnova, E. K. Egorova, E. I. Pustovaya, A. B. Sudarikov, A. O. Abdullaev, L. A. Gorgidze, D. I. Chebotarev
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 95-99 (2020)
Primary myelofibrosis is a myeloproliferative neoplasm that occurs de novo, characterized by clonal proliferation of stem cells, abnormal expression of cytokines, bone marrow fibrosis, hepatosplenomegaly as a result of extramedullary hematopoiesis, s
Externí odkaz:
https://doaj.org/article/c76c7b7e9a0b424fa8e1fe9422cfda33
Autor:
A. L. Melikyan, E. I. Pustovaya, E. K. Egorova, M. V. Kalinina, T. I. Kolosheynova, I. N. Subortseva, E. A. Gilyazitdinova, V. N. Dvirnyk
Publikováno v:
Онкогематология, Vol 12, Iss 1, Pp 78-87 (2017)
The article presents a systematic diagnostic approach for thrombocytopenia, as well as the results of practical implementation of thrombocytopenia diagnostic protocol in adult patients. Among 183 patients first admitted to HRC with unspecified origin
Externí odkaz:
https://doaj.org/article/f636fc4f30cf4f61b11ce928e4446318
Autor:
A L MELIKYAN, I N SUBORTSEVA, E A GILYAZITDINOVA, T I KOLOSHEJNOVA, E I PUSTOVAYA, E K EGOROVA, A M KOVRIGINA, A B SUDARIKOV, A O ABDULLAEV, E G LOMAIA, N T SIORDIYA, A Yu ZARITSKEY, V G SAVCHENKO
Publikováno v:
Терапевтический архив, Vol 90, Iss 7, Pp 23-29 (2018)
Purpose of the study. A comparative evaluation of the effectiveness of different therapeutic strategies in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Materials and methods. Patients with PV or ET, diagnosed according to
Externí odkaz:
https://doaj.org/article/24b0a0e7af394e34811b114da05d6bfc
Autor:
A L Melikyan, I N Subortseva, A B Sudarikov, A M Kovrigina, E A Gilyazitdinova, T I Kolosheinova, A O Abdullaev, S A Treglazova
Publikováno v:
Терапевтический архив, Vol 89, Iss 7, Pp 4-9 (2017)
The aim of the present paper was to evaluate the clinical features and risk of thrombotic events (TE) in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), depending on the molecular characteristics of disease. Clinical dat
Externí odkaz:
https://doaj.org/article/fff1484298094c0d95e324ea2cf2b148
Autor:
A L Melikyan, E K Egorova, А М Kovrigina, I N Subortseva, E A Gilyazitdinova, S R Karagyulyan, M A Silaev, E G Gemdzhian, V G Savchenko
Publikováno v:
Терапевтический архив, Vol 87, Iss 7, Pp 64-71 (2015)
Aim. To study the clinical features of Castleman’s disease (CD) and to elaborate therapeutic approaches in its different morphological types. Subjects and methods. The clinical and laboratory data were studied in 59 prospectively examined patients
Externí odkaz:
https://doaj.org/article/2f541c08aee04f028aa9979b94beedf5
Autor:
Gennadiy Martinovich Galstyan, Mikhail Yur'evich Drokov, Svetlana Aleksandrovna Katrysh, Galina Aleksandrovna Klyasova, Elena Aleksandrovna Gilyazitdinova, Tat'yana Igorevna Karpova, Boris Ivanovich Marakusha, Igor' Semenovich Tartakovskiy, G M Galstyan, M Yu Drokov, S A Katrysh, G A Klyasova, E A Gilyazitdinova, T I Karpova, B I Marakusha, I S Tartakovsky
Publikováno v:
Терапевтический архив, Vol 83, Iss 7, Pp 61-65 (2011)
A male patient received non-chemotherapeutic drugs which induced deep neutropenia complicated with sepsis, bilateral pneumonia, acute respiratory insufficiency. Artificial pulmonary ventilation was applied. The examination of bronchoalveolar lavage s
Externí odkaz:
https://doaj.org/article/1ec625354f394509affbdcd3f68dcba8
Autor:
Varvara Ivanovna Zamyatina, Aminat Umaraskhabovna Magomedova, Sergey Kirillovich Kravchenko, Elena Aleksandrovna Gilyazitdinova, Elena Alekseevna Ilyushkina, Evgeniy Evgen'evich Zvonkov, Irina Borisovna Kaplanskaya, Tat'yana Nikiforovna Obukhova, Galina Aleksandrovna Klyasova, Lana Anzorovna Gorgidze, Zhanna Valentinovna Churakova, Aleksandra Mikhaylovna Kremenetskaya, Andrey Ivanovich Vorob'ev, V I Zamyatina, A U Magomedova, S K Kravchenko, E A Gilyazitdinova, E A Ilyushkina, E E Zvonkov, I B Kaplanskaya, T N Obukhova, G A Klyasova, L A Gorgidze, Zh V Churakova, A M Kremenetskaya, A I Vorobyev
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 71-75 (2009)
Primary skin large B-cell lymphosarcomas (PLBCL) present with skin lesions, other organs and systems are not involved. As CHOP courses are not high effective in PLBCL, we were the first to treat a patient with modified block therapy NHL BFM-90. A com
Externí odkaz:
https://doaj.org/article/1c3b72ef41e2402d8ca733239c6368f7
Autor:
I N Subortseva, Zh V Tratsevskaya, E A Koloshejnova, A L Melikyan, O V Margolin, L A Gorgidze, K S Shashkina, E A Gilyazitdinova
Publikováno v:
Терапевтический архив, Vol 91, Iss 7, Pp 93-99 (2019)
Thrombosis is a serious and extremely dangerous disease that has a negative impact on the quality and longevity. Antiphospholipid syndrome (APS) is a pathology characterized by recurring venous, arterial, microvasculature thrombosis, pregnancy pathol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae21a7725dd4eabb978badcee8b63ba
https://pubmed.ncbi.nlm.nih.gov/32598741
https://pubmed.ncbi.nlm.nih.gov/32598741
Autor:
I N Subortseva, Alla M. Kovrigina, EK Egorova, A O Abdullaev, Andrey Sudarikov, EI Pustovaya, E A Gilyazitdinova, T I Kolosheinova, A L Melikyan
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 11, Iss 3, Pp 252-258 (2018)
Hydroxycarbamide is an antitumor agent mainly used for treatment of Ph-negative myeloproliferative disorders and sickle cell disease. The development of skin ulcers is a rare but serious adverse event in long-term antitumor therapy. Hydroxycarbamide-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3837c20e602b0007183a1c7306c458ed
https://doi.org/10.21320/2500-2139-2018-11-3-252-258
https://doi.org/10.21320/2500-2139-2018-11-3-252-258
Autor:
Sergey Dubov, Valery G. Savchenko, Lev S. Butaev, Hunan Julhakyan, Yulia Sveshnikova, Inessa Yu. Toropova, Oksana Ochirova, Olga A. Gavrilina, E A Gilyazitdinova, Aleksandr A. Siniaev, Vasily Shuvaev, Anastasia N. Vasileva, Lubov Gavrilova, Maria Grishunina, Kristina Zakurdaeva, Mikhail A. Kunst, Marina O. Popova, Vladimir I. Vorobyev, K D Kaplanov, Al'-Radi Ls, Andrei Petrenko, Yulia A. Chabaeva, Daria Baryshnikova, Vitaly S. Dubov
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background Patients (pts) with lymphoproliferative diseases (LPD) are at high risk of COVID-19 severe and lethal course. Objective To evaluate treatment outcomes and risk factors in pts with LPD and COVID-19 in a real-world setting. Methods CHRONOS19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac386586f20ac7457204c2d72791da1
http://europepmc.org/articles/PMC8404062
http://europepmc.org/articles/PMC8404062